Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025

Rhea-AI Summary

Picard Medical (NYSE American: PMI) will present in vitro benchtop data for the fully implantable Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025) in Vienna, Austria, Dec 1–4, 2025.

The company’s presentation is scheduled for Thursday, December 4, 2025 at 14:05 CET in Mini Oral Session 3: Hemocompatibility and Heart/Pump Interaction. Presenter: Duffy Elmer, Engineering Project Manager. The Emperor platform uses an internal motor driven design that removes the need for an external pneumatic driver and is engineered to improve patient mobility and quality of life.

News Market Reaction

+1.95%

1 alert

+1.95% News Effect

+$3M Valuation Impact

$172M Market Cap

0.2x Rel. Volume

On the day this news was published, PMI gained 1.95%, reflecting a mild positive market reaction. This price movement added approximately $3M to the company's valuation, bringing the market cap to $172M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: December 1–4, 2025 Presentation date: Thursday, December 4, 2025 Presentation time: 14:05 CET +1 more

4 metrics

Conference dates December 1–4, 2025 ISMCS 2025 meeting window in Vienna

Presentation date Thursday, December 4, 2025 Scheduled Emperor TAH data presentation

Presentation time 14:05 CET Mini Oral Session 3 slot for Emperor TAH data

Conference edition 31st Annual Meeting International Society for Mechanical Circulatory Support (ISMCS 2025)

Market Reality Check

Price: $1.56 Vol: Volume 482,950 is only 0....

low vol

$1.56 Last Close

Volume Volume 482,950 is only 0.19x the 20-day average 2,536,297, indicating subdued trading interest pre‑event. low

Technical Shares at $2.47 are trading below the 200-day MA of $2.69 and remain 81.94% under the 52-week high.

Peers on Argus

PMI was up 3.05% while key medical device peers were flat to down (e.g., CTKB -0...

PMI was up 3.05% while key medical device peers were flat to down (e.g., CTKB -0.6%, KIDS -2.96%, LAB -1.33%), suggesting a stock-specific move tied to its artificial heart platform rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Durability milestone	Positive	-8.7%	Record <b>2,900 days</b> of continuous SynCardia artificial heart support.
Dec 03	Conference presentation	Positive	+2.0%	CEO presenting Emperor Total Artificial Heart data at CSI Focus D-HF.
Nov 26	Data presentation news	Positive	+1.9%	Announcement of in vitro benchtop data presentation for Emperor TAH at ISMCS.
Nov 19	Pre-clinical milestone	Positive	-6.7%	First in vivo Emperor TAH implantations in three pre-clinical models.
Nov 14	Earnings and IPO update	Neutral	+10.7%	Q3 2025 results plus IPO proceeds and balance sheet changes.

Pattern Detected

News on the Emperor Total Artificial Heart has produced mixed reactions: two positive technical milestones led to price declines, while conference and presentation updates saw modest gains.

Recent Company History

Over the last month, Picard highlighted multiple milestones around the SynCardia and next‑generation Emperor Total Artificial Heart platforms, including first in vivo implantations and extended multi‑year patient support on the legacy device. Conference and data‑presentation updates on Dec 3 and Dec 4, 2025 were followed by modest gains of 2.02% and 1.95%, while clinically significant Emperor milestones on Nov 19 and durability news on Dec 9 coincided with declines of 6.69% and 8.71%. Q3 earnings on Nov 14 saw a stronger 10.66% move.

Market Pulse Summary

This announcement highlights Picard’s plan to present in vitro benchtop data on its fully implantabl...

Analysis

This announcement highlights Picard’s plan to present in vitro benchtop data on its fully implantable Emperor Total Artificial Heart at ISMCS 2025, emphasizing an internal motor design intended to remove external pneumatic drivers and improve mobility. Recent filings and prior news show parallel progress through pre‑clinical implantations and multiple conference presentations. Investors may watch for follow‑on clinical data, funding developments, and any updates to the company’s going‑concern language as indicators of execution and balance‑sheet risk.

Key Terms

in vitro, total artificial heart, International Society for Mechanical Circulatory Support, hemocompatibility, +1 more

5 terms

in vitro medical

"it will present in vitro data on the fully implantable Emperor"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

total artificial heart medical

"maker of the world’s first total artificial heart approved by both"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

International Society for Mechanical Circulatory Support medical

"at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support"

An international society for mechanical circulatory support is a professional organization of doctors, researchers and engineers who focus on devices and treatments that help or replace the heart’s pumping function, such as ventricular assist devices and external support systems. Investors watch its guidelines, registry data and conference findings because they influence clinical standards, device adoption, regulatory expectations and how the market judges which technologies are safe, effective and likely to gain or lose market share — like a referee and scoreboard for the field.

hemocompatibility medical

"Mini Oral Session 3: Hemocompatibility and Heart/Pump Interaction"

Hemocompatibility is how well a medical device or material interacts with blood without causing clots, damaging blood cells, or triggering harmful immune reactions. For investors, it matters because poor hemocompatibility can derail regulatory approval, increase clinical risks, raise development costs, and limit market adoption—think of it like a nonstick surface for blood: the more 'blood‑friendly' the product, the smoother its path to use and commercial success.

pneumatic driver technical

"eliminates the need for any external pneumatic driver and is engineered"

A pneumatic driver is a hand-held or mounted tool that uses compressed air to deliver rotational or percussive force for driving screws, bolts or fasteners — like an air-powered screwdriver or impact wrench instead of an electric one. Investors care because these tools affect production speed, maintenance and safety costs, and capital spending; a factory’s choice of pneumatic equipment can influence operating efficiency, margins and exposure to supply or regulatory changes in compressed-air systems.

AI-generated analysis. Not financial advice.

TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will present in vitro data on the fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025), held in Vienna, Austria from December 1^st through 4^th, 2025.

Details of the presentation are below:

Date: Thursday, December 4, 2025
Time: 14:05 Central European Time (CET).
Session: Mini Oral Session 3: Hemocompatibility and Heart/Pump Interaction
Presentation Title: “The Emperor Total Artificial Heart: A Next Generation, Fully Implantable Total Artificial Heart”
Presenter: Duffy Elmer, Engineering Project Manager, Picard Medical, Inc.

The presentation will highlight benchtop performance data from the Emperor, SynCardia’s fully implantable next generation Total Artificial Heart platform. The system uses an internal motor driven design that eliminates the need for any external pneumatic driver and is engineered to significantly improve patient mobility and quality of life.

About ISMCS 2025
ISMCS 2025 is the 31st annual global congress of the International Society for Mechanical Circulatory Support. The meeting brings together researchers, clinicians, engineers and industry leaders in mechanical circulatory support. It provides a forum to review new clinical research, discuss emerging technologies, and highlight next generation device innovations.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When will Picard Medical (PMI) present the Emperor Total Artificial Heart at ISMCS 2025?

Picard Medical will present on Thursday, December 4, 2025 at 14:05 CET during ISMCS 2025 in Vienna.

What data will Picard Medical (PMI) show for the Emperor Total Artificial Heart at ISMCS 2025?

The company will present in vitro benchtop performance data on the Emperor fully implantable Total Artificial Heart.

Which session and topic will Picard Medical (PMI) appear in at ISMCS 2025?

The presentation is in Mini Oral Session 3: Hemocompatibility and Heart/Pump Interaction on December 4, 2025.

Who is presenting Picard Medical’s (PMI) Emperor TAH data at ISMCS 2025?

Duffy Elmer, Engineering Project Manager for Picard Medical will present the Emperor TAH data.

How does the Emperor Total Artificial Heart design differ from current SynCardia systems?

The Emperor uses an internal motor driven design that eliminates the need for any external pneumatic driver.

What patient benefits does Picard Medical (PMI) claim for the Emperor Total Artificial Heart?

The system is engineered to significantly improve patient mobility and quality of life by removing external pneumatic hardware.